$Cellectar BioSciences (CLRB.US)$ Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(1.40) per share which beat the analyst consensus estimate of $(1.59) by 11.95 percent. This is a 60 percent increase over losses of $(3.50) per share from the same period last year.

$Alterity Therapeutics (ATHE.US)$ JPMorgan Chase Acquires Significant Stake in Alterity Therapeutics

$X4 Pharmaceuticals (XFOR.US)$ X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025

$Virpax Pharmaceuticals (VRPX.US)$
Virpax Looking to Use MET to Develop Intranasal COVID Vaccine
Business Wire 7-Mar-2025 8:00 AM
Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, is looking to use Molecular Envelope Technology (MET) or a similar technology to deliver a mRNA COVID vaccin...

$Virpax Pharmaceuticals (VRPX.US)$ Virpax Looking to Use Met to Develop Intranasal Covid Vaccine

$Virpax Pharmaceuticals (VRPX.US)$ Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, is pleased to announce its NES100 dose range finding toxicity study will be presented at The Society of Toxicology (SOT) 64th annual meeting and Tox Expo taking place March 16-20th in Orlando, FL. Th...

$Cellectar BioSciences (CLRB.US)$ Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025

$Virpax Pharmaceuticals (VRPX.US)$ Virpax Pharmaceuticals, a preclinical-stage pharmaceutical company, reported a reduced net loss of $12.1M for FY2024, down from $15.2M in FY2023. R&D expenses increased to $5.8M from $5.1M, while general and administrative expenses decreased significantly to $6.3M from $10.6M. The company ended the year with a cash position of $1.5M and an accumulated deficit of $71.6M.The company completed a $6M public offering in January 2025, issuing 3.45M shares and 26...